Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15502774 | 0.90 | HTR1A (0.45) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13044292 | 0.88 | GRM4 (0.46) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13552742 | 0.88 | FABP4 (0.47) | HTR1AHTR2AHTR7HTR6HSP90AA1 | |
| SCHEMBL13044303 | 0.88 | HSP90AA1 (0.46) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13552698 | 0.86 | HTR1A (0.48) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13552734 | 0.85 | ALDH1A1 (0.46) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13044299 | 0.84 | CCNB2 (0.47) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13552714 | 0.83 | HTR1A (0.57) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13552894 | 0.83 | HTR1A (0.58) | MEN1KMT2AHTR1AHTR2AHTR7 | |
| SCHEMBL13552693 | 0.82 | USP28 (0.53) | MEN1KMT2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2440048-B1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2010144586-A1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | MEN1 1016/4885KMT2A 2378/4885HTR1A 4175/4885 |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | MEN1 1456/4885KMT2A 1798/4885HTR1A 1574/4885 |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | MEN1 1016/4885KMT2A 2378/4885HTR1A 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.